Reva Medical, a San Diego, CA-based leader in bioresorbable polymer technologies for vascular applications, closed a $45m Series B equity financing.
The round was led by a global strategic investor with deep experience in medical devices, as well as BioStar Capital, and existing investors.
Proceeds from the financing will be used to fund the company’s ongoing operating, clinical and capital needs, including the clinical program for its MOTIV® Peripheral Vascular Bioresorbable Scaffold.
Led by President and Chief Executive Offer Jeffrey Anderson, Reva Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. Thecompany’s products include MOTIV bioresorbable scaffolds for the treatment of peripheral artery disease, Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease, and TyroSphere embolic beads.